AperTO - Archivio Istituzionale Open Access dell'Università di Torino

Microangiopathic hemolytic anemia caused by a signet-ring cell carcinoma of the intrahepatic bile duct

This is the author's manuscript

Original Citation:

Availability:

This version is available <http://hdl.handle.net/2318/1717394> since 2019-11-24T16:45:58Z

Terms of use:

Open Access

Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)

TITLE PAGE

Microangiopathic haemolytic anaemia caused by a signet-ring cell carcinoma of the intrahepatic bile duct.

Corresponding author:

Ibrahim Kamal Jouness, Ramy; MD

Address: University of Turin, Department of Medical Science, Division of Gastroenterology, Corso Dogliotti 14 – 10126 – Turin - Italy

e-mail: ibrahim.massimo@gmail.com

Phone number: +39 3391125488

Authors' names and institution:

Ibrahim Kamal Jouness, Ramy; MD, University of Turin, Department of Medical Science, Division of Gastroenterology;

Ponzo, Paola; MD, University of Turin, Department of Medical Science, Division of Gastroenterology;

Marzano, Alfredo; MD, University of Turin, Department of Medical Science, Division of Gastroenterology.

Affiliation:

Università degli Studi di Torino

Città della Salute e Della Scienza di Torino

Department of Medical Sciences

Division of Gastroenterology

Corso Dogliotti 14 – 10126 – Turin - Italy

Key words: *anemia, biliary duct carcinoma, gastric cancer, hepatobiliary surgery, immunohistopathology*

Microangiopathic haemolytic anaemia caused by a signet-ring cell carcinoma of the intrahepatic bile duct.

Ramy Ibrahim Kamal Jouness, Paola Ponzio and Alfredo Marzano

SUMMARY

Microangiopathic haemolytic anaemia (MAHA) originates from a mechanical injury of red cells, caused by vascular thrombosis or stenosis. Cancer is a cause of MAHA as a consequence of both chemotherapy and disseminated disease itself. Here we describe the case of a 60-year-old man who developed a signet-ring cell carcinoma originated from the intrahepatic bile ducts, complicated by bone marrow metastasis and MAHA.

INTRODUCTION

Cholangiocarcinoma is an uncommon adenocarcinoma of bile ducts, with an annual incidence rate in Europe of 1.5 cases per 100,000. [1] The frequency is higher in patients with biliary-enteric surgical drainage, mainly in those who develop recurrent biliary infections. [2]. In parallel, cirrhosis is a risk factor for the development of intrahepatic cholangiocarcinoma.

Signet-ring cell carcinoma (SRCC) is an extremely rare and dedifferentiated subtype of bile ducts carcinoma. Only a few cases of SRCC of the bile ducts are described in literature, all of them originating from extrahepatic bile ducts.

Microangiopathic haemolytic anaemia (MAHA) is a form of haemolytic anemia deriving from a mechanical injury of red cells, caused by vascular thrombosis or stenosis. An essential feature of

this anaemia is the detection of red cell fragments (schistocytes) on peripheral-blood smear. [3] Cancer can be a cause of MAHA, as a consequence of both chemotherapy and disseminated disease itself.

Here we describe the case of a 60-year-old cirrhotic patient who developed a signet-ring cell carcinoma originated from the intrahepatic bile ducts twenty years after a transduodenal sphincteroplasty and complicated by bone marrow metastasis and MAHA. To the best of our knowledge, this is the only case of MAHA caused by bile duct carcinoma and of signet-ring cell carcinoma of the intrahepatic biliary system.

CASE REPORT:

A 60-year-old man was admitted to our hospital for worsening anaemia (Hb 5.6 g/dl), dyspnoea and diffused spontaneous haematomas. Past medical history included dextrocardia, alcohol-related cirrhosis, chronic obstructive pulmonary disease (COPD), cholecystectomy and transduodenal sphincteroplasty.

The patient underwent an emergency esophagogastroduodenoscopy (EGD) showing haemorrhagic gastritis with oozing haemorrhage (Forrest Ib) treated with injection of dilute adrenaline. Subsequently, he received red blood cell transfusions along with platelet infusions because of the detected thrombocytopenia (PLTS 24,000/mm³).

Despite transfusion therapy, anaemia continued to worsen. Laboratory analysis showed high levels of lactate dehydrogenase (LDH) (4,546 IU/l), total bilirubin (4.6 mg/dl), indirect bilirubin (2.6 mg/dl), reticulocytes ($258 \times 10^9/l$), and alkaline phosphatase (ALP) (296 UI/l) accompanied by low levels of haptoglobin (<10 mg/dl) while direct Coombs test was negative. Coagulation tests were abnormal (INR 1.38; aPTT 47 s). Supposing an haemolytic anaemia the blood smear was analysed

and it revealed the presence of anisopoikilocytosis with abundant schistocytes (25% of the erythrocytes). On the basis of these findings a diagnosis of MAHA was made while thrombocytopenia and coagulation abnormalities were considered related to the underlying cirrhosis.

On the other hand, high levels of Carcinoembryonic Antigen (2,125 ng/ml) were also detected while Carbohydrate Antigen 19-9 (CA 19-9) and Alpha Fetoprotein (AFP) were within the normal range. Several examinations were performed in order to find out the presence of an occult carcinoma. Colonoscopy and EGD results were negative but the abdominal computed tomography (CT) showed adenopathy at the porta hepatis and pneumobilia in the left part of the intrahepatic biliary system associated to distension of the extrahepatic bile ducts and a fistula connecting the second duodenal portion and the common bile duct.

A bone marrow biopsy was also performed and it demonstrated a metastatic invasion from signet-ring shaped cells derived from an adenocarcinoma (Fig. 1-2). Immunohistochemical analysis was positive for cytokeratin 7 (CK7) and pancytokeratin (AE1/AE3) while cytokeratin 20 (CK20), caudal type homeobox transcription factor 2 (CDX2), thyroid transcription factor-1 (TTF-1) and acid phosphatase stains were negative (Fig. 3).

Positron Emission Tomography (PET) scanning with 18-fluorodeoxyglucose (18-FDG) revealed an increased uptake of radionuclide in all skeletal portions, in the intrahepatic biliary system (segment S2 and S4) and at the porta hepatis and celiac trunk (Fig.4).

According to PET scanning and to the histological result the location of the primary tumour was identified as the intrahepatic bile ducts.

Patient's clinical condition worsened, with the progression of dyspnoea and the onset of bone pain. The patient died 17 days after the admission.

DISCUSSION:

MAHA can complicate the course of tumoural disease and it is frequently associated with bone marrow metastasis [4, 5], but its pathogenesis in cancer remains unclear. It seems that substances secreted by tumour cells (in particular cytokines and mucine) can cause endothelial injury, with subsequent red blood cells fragmentation. The presence of bone marrow metastasis can simultaneously worsen the anaemia by adding an hyporegenerative component.

Typical features of MAHA are high levels of LDH, indirect bilirubin, reticulocytes and a decrease in haptoglobin levels with schistocytes on peripheral-blood smear and negative direct Coombs test [6]. All these features were identified in our patient,. In this case, anaemia was worsened by the concomitant chronic liver disease (mainly because of the associated hypersplenism) and by alcohol intake and bone marrow metastasis (both causing an hyporigenerative anaemia).

Bone marrow biopsy showed a metastatic invasion from signet-ring shaped cells (SRCC), which is an extremely rare subtype of bile ducts carcinoma. It is a dedifferentiated adenocarcinoma, histologically characterized by round-shaped cells, with peripherally placed nuclei and cytoplasmic vacuoles filled with mucin [7, 8]. SRCC is usually located in the stomach but can also be found in other tissues like prostate [9], breast [10], testis [11] and ovary [12], bladder [13], lung [14], colon [15], gallbladder [16] and Vater ampulla [17]. To the best of our knowledge only 5 cases of SRCC of the bile ducts are described in literature, all of them referring to extrahepatic bile ducts SRCC [18, 19, 20, 21, 22].

According to the PET scanning results, the primary location of the SRCC in our patient was the intrahepatic biliary system (segment S2 and S4). At the same time, our patient had a history of transduodenal sphincteroplasty that supports this theory. Sphincteroplasty was a procedure used for treating benign distal common bile duct obstruction. It is a mucosa-to-mucosa suture, either of duodenum to bile duct alone (biliary sphincteroplasty) or of bile duct to pancreatic duct in addition

(pancreatic sphincteroplasty). This procedure creates a permanent destruction of the Oddi's sphincter [23, 24].

It is known that the frequency of bile duct carcinoma is higher in patients with biliary-enteric surgical drainage, mainly in those who develop recurrent biliary infections. A study pointed out an incidence of bile duct carcinoma of 5.8% after transduodenal sphincteroplasty. [2] It seems that bile and pancreatic secretions can cause a chronic injury in bile ducts, resulting in premalignant or malignant changes in the biliary epithelium. Recurrent cholangitis can contribute to the chronic mucosal damage. Cholangiocarcinoma arising after a biliary-enteric drainage are often multifocal, supporting the hypothesis of toxic carcinogenesis affecting the biliary epithelium, causing a field change, even involving intrahepatic ducts. At the same time, our patient had alcohol-related cirrhosis, that is an additional risk factor for cholangiocarcinoma. [25]

This is the only case of SRCC deriving from the intrahepatic biliary system and the only case of MAHA related to a bile duct carcinoma.

Cancer – related MAHA is more frequently associated to respiratory symptoms and bone pain than non-cancer-related MAHA, and our patient developed both. [26] The prognosis of cancer - related MAHA is poor and a standard therapy is not well established. [3, 27]

REFERENCES

1. Mosconi S, Beretta GD, Labianca R, Zampino MG, Gatta G, Heinemann V. Cholangiocarcinoma. *Crit Rev Oncol Hematol*. 2009 Mar;69(3):259-70
2. Tocchi A, Mazzoni G, Liotta G, Lepre L, Cassini D, Miccini M. Late development of bile duct cancer in patients who had biliary-enteric drainage for benign disease: a follow-up study of more than 1,000 patients. *Ann Surg*. 2001 Aug;234(2):210-4
3. Antman KH, Skarin AT, Mayer RJ, Hargreaves HK, Canellos GP. Microangiopathic Hemolytic anemia and cancer: a review. *Medicine (Baltimore)*. 1979 Sep; 58(5): 377-84
4. Ataga KI, Graham ML. Microangiopathic haemolytic anemia associated with metastatic breast carcinoma. *Am J Hematol*. 1999 Aug;61(4): 254-5
5. Sakai C, Takagu T, Oguro M, Wakatsuki S, Kuwahara T. Malignant pheocromocytoma accompanied by microangiopathic haemolytic anemia: a case report. *Jpn J Clin Oncol*. 1994 Jun;24(3):171-4
6. Shin SY, Park H, Chae SW, Woo HY. Microangiopathic haemolytic anemia as the first manifestation of metastatic signet ring cell carcinoma of unknown origin: a case report and review of literature: *Korean J Lab Med*. 2011 Jul; 31(3):157-61
7. Fukui Y. Mechanisms behind signet ring cell carcinoma formation. *Biochem Biophys Res Commun*. 2014 Aug 8; 450(4):1231-3
8. Bosman FT, Carneiro F, Hruban RH, Theise ND. WHO classification of tumors of the digestive system. 4th ed. Lyon:IARC Press;2010

9. Celik o, Budak S, Ekin G, Akarken I, Ilbey YO. A case with primary signet ring cell adenocarcinoma of the prostate and review of the literature. Arch Ital Urol Androl. 2014 Jun 30;86(2):148-9
10. Sandhu J, Dubey VK, Makkar M, Suri V. Pure primary signet ring cell carcinoma breast: A rare cytological diagnosis. J Cytol 2013 Jul; 30(3):204-6
11. Michal M, Hes O, Kazakov DV. Primary signet-ring stromal tumor in testis. Virchows Arch. 2005 Jul; 447(1):107-10
12. Matsumoto M, Hayashi Y, Ohtsuki Y, Ikegami N, Toi M, Iguchi M, Hiroi M. Signet-ring stromal tumor of the ovary: an immunoistochemical and ultrastructural study with a review of the literature. Med Mol Morphol. 2008 Sep; 41(3):165-70
13. El Ammari JE, Ahsaini M, Riyach O, El Fassi MJ, Farih MH, Hammas N, Elfatmi H, Amarti A. Primari signet-ring cell carcinoma of the urinary bladder successfully managed with cisplatin and gemcitabine: a case report. J Med Case Rep. 2013 Feb 6;7:37
14. Livieratos S, Smith JK, Fatakhov E, Koch CF Jr. Primary signet ring cell carcinoma of the lung a rare subtype. BMJ Case Rep. 2013 Sep 20; 2013
15. Makino T, Tsujinaka T, Mishima H, Ikenaga M, Sawamura T, Nakamori S, Fujitani K, Hirao M, Kashiwazaki M, Masuda N, Takeda M, Mano M. Primary signet-ring cell carcinoma of the colon and rectum: report of eight cases and review of 154 Japanese cases. Hepatogastroenterology. 2006 Nov-Dec;53(72):845-9
16. Bazan F, Sanchez J, Aguilar G, Radosevic A, Busto M, Zuccarino F, Pijuan L, Risueno N. Metastatic gallbladder adenocarcinoma with signet-ring cells: A case report. J Med Case Rep. 2011 Sep 14;5:458

17. Acharya MN, Panagiotopoulos N, Cohen P, Ahmad R, Jiao LR. Poorly-differentiated signet-ring cell carcinoma of the ampulla of Vater: report of a rare malignancy. *JOP*. 2013 Mar 10;14(2):190-4
18. Hiraki M, Yakushiji H, Hashiguchi K, et al. Signet ring cell carcinoma of the lower bile duct with rapid growth: report of a case. *Hepatogastroenterology*. 2007; 54:1922–1924
19. Ogata S, Kimura A, Hatsuse K, et al. Poorly differentiated adenocarcinoma with signet-ring cell carcinoma of the extrahepatic bile duct in a 42-year-old Japanese female: a case report. *Acta Med Okayama*. 2010; 64:63–65
20. Lee EY, Kim C, Kim MJ, et al. Signet ring cell carcinoma of the extrahepatic bile duct. *Gut Liver*. 2010; 4:402–406
21. Kwon HJ, Yoon GS, Kwon YC, Kim SG, Jeong JY. Signet-ring cell carcinoma of the distal common bile duct: report of a case. *Korean J Pathol*. 2014 Aug;48(4):315-8
22. Matsumoto T, Inoue S, Masuo K, Okamoto Y, Fukushima M, Wada M, Shimeno N, Kimoto N, Fujita M, Sugino Y, Okada A, Inokuma T, Imai Y. Signet ring cell carcinoma of the bile duct: a case report. *Nihon Shokakibyo Gakkai Zasshi*. 2001 Dec;108(12):2042-9
23. Watanabe P, Williamson RC. Pancreatic sphincterotomy and sphincteroplasty. *Gut*. 1992 Jul; 33(7):865-7
24. Jones SA, Steedman RA, Keller TB, Smith LL. Transduodenal sphincteroplasty (not sphincterotomy) for biliary and pancreatic disease. Indications, contraindications, and results. *Am J Surg*. 1969 Aug; 11(8):292-306
25. Bettschart V, Clayton R A E, Parks R W, Garden O J, Bellamy C O C. Cholangiocarcinoma arising after biliary-enteric drainage procedures for benign disease. *Gut*. 2002; 51(1): 128-129

26. Oberic L, Buffet M, Schwarzingen M, Veyradier A, Clabault K, Malot S, et al. Cancer awareness in atypical thrombotic microangiopathies. *Oncologist* 2009;14:769-79.
27. Abdel Samie A, Sandritter B, Theilmann L. Severe microangiopathic hemolytic anemia as first manifestation of a CUP syndrome. Rapid hematologic remission under polychemotherapy. *Med Klin (Munich)* 2004;99:148–153